Diabetes, Medication Side Effects, Obesity
Conditions
Keywords
GLP-1, Incretin mimetic, medication management, side effect management
Brief summary
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Interventions
OTHERAIManage
GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.
Sponsors
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Provider Eligibility Criteria (Phase 1) * Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics, * Provide care to at least 5 patients prescribed an IMM. Patient Eligibility Criteria (Phase 1) * (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age.
Exclusion criteria
Provider
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness | Day 1 (60 minutes) | In Phase 1, qualitative data regarding perceived usefulness will be collected. |
| Percentage of Patients who Complete Qualitative Measure - Perceived Usability | Day 1 (60 minutes) | In Phase 1, qualitative data regarding perceived usability will be collected. |
| Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges | Day 1 (60 minutes) | In Phase 1, qualitative data regarding perceived use challenges will be collected. |
| Percentage of Patients who Complete Qualitative Measure - Perceived Value | Day 1 (60 minutes) | In Phase 1, qualitative data regarding perceived value will be collected. |
Countries
United States
Contacts
CONTACTElizabeth Stevens, PhD, MPH
PRINCIPAL_INVESTIGATORElizabeth Stevens, PhD, MPH
NYU Langone Health
Outcome results
None listed